Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.09)
# 2,902
Out of 5,179 analysts
112
Total ratings
30.77%
Success rate
-1.19%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $8.91 | +45.90% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $20.50 | +56.10% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $2.29 | +293.01% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $106.62 | -10.90% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $12.29 | +103.42% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $3.81 | +214.96% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $8.94 | +34.23% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $2.68 | +161.19% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.12 | +78.57% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $13.34 | +27.44% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $2.21 | +307.24% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $16.96 | +171.23% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.07 | +647.66% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $31.28 | -23.27% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.78 | +124.72% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.19 | +73.41% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.82 | +449.74% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $2.82 | +467.38% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.26 | +177.78% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.20 | +1,171.62% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $8.67 | +2,879.24% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $8.91
Upside: +45.90%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $20.50
Upside: +56.10%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $2.29
Upside: +293.01%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $106.62
Upside: -10.90%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $12.29
Upside: +103.42%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $3.81
Upside: +214.96%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $8.94
Upside: +34.23%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.68
Upside: +161.19%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.12
Upside: +78.57%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $13.34
Upside: +27.44%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $2.21
Upside: +307.24%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $16.96
Upside: +171.23%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.07
Upside: +647.66%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $31.28
Upside: -23.27%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.78
Upside: +124.72%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $5.19
Upside: +73.41%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.82
Upside: +449.74%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $2.82
Upside: +467.38%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.26
Upside: +177.78%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.20
Upside: +1,171.62%
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $8.67
Upside: +2,879.24%